Butyrate as a promising therapeutic target in cancer: From pathogenesis to clinic (Review)

Int J Oncol. 2024 Apr;64(4):44. doi: 10.3892/ijo.2024.5632. Epub 2024 Mar 1.

Abstract

Cancer is one of the leading causes of mortality worldwide. The etiology of cancer has not been fully elucidated yet, and further enhancements are necessary to optimize therapeutic efficacy. Butyrate, a short‑chain fatty acid, is generated through gut microbial fermentation of dietary fiber. Studies have unveiled the relevance of butyrate in malignant neoplasms, and a comprehensive understanding of its role in cancer is imperative for realizing its full potential in oncological treatment. Its full antineoplastic effects via the activation of G protein‑coupled receptors and the inhibition of histone deacetylases have been also confirmed. However, the underlying mechanistic details remain unclear. The present study aimed to review the involvement of butyrate in carcinogenesis and its molecular mechanisms, with a particular emphasis on its association with the efficacy of tumor immunotherapy, as well as discussing relevant clinical studies on butyrate as a therapeutic target for neoplastic diseases to provide new insights into cancer treatment.

Keywords: GPCR; HDACI; butyrate; cancer; treatment; tumor immunity.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Butyrates* / pharmacology
  • Butyrates* / therapeutic use
  • Dietary Fiber
  • Humans
  • Neoplasms* / drug therapy
  • Receptors, G-Protein-Coupled

Substances

  • Antineoplastic Agents
  • Butyrates
  • Dietary Fiber
  • Receptors, G-Protein-Coupled

Grants and funding

The present study was supported by the National Natural Science Foundation of China (grant no. 82203056), the Natural Science Foundation of Liaoning (grant no. 2023-BS-167), the Science and Technology Talent Innovation Support Plan of Dalian (grant no. 2022RQ091) and the '1+X' program for Clinical Competency Enhancement-Clinical Research Incubation Project of the Second Hospital of Dalian Medical University (grant no. 2022LCYJYB01).